Zosano Pharma (NASDAQ:ZSAN) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Thursday.
Separately, BTIG Research set a $19.00 price objective on Zosano Pharma and gave the stock a “buy” rating in a research report on Wednesday, September 26th.
ZSAN opened at $3.47 on Thursday. Zosano Pharma has a 1-year low of $3.29 and a 1-year high of $25.70.
Zosano Pharma (NASDAQ:ZSAN) last posted its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.14.
A number of hedge funds have recently bought and sold shares of the business. Millennium Management LLC bought a new position in Zosano Pharma during the 1st quarter worth $629,000. First Republic Investment Management Inc. bought a new position in Zosano Pharma during the 2nd quarter worth $284,000. FNY Investment Advisers LLC bought a new position in Zosano Pharma during the 2nd quarter worth $197,000. CIBC Private Wealth Group LLC bought a new position in Zosano Pharma during the 2nd quarter worth $131,000. Finally, Northern Trust Corp bought a new position in Zosano Pharma during the 2nd quarter worth $119,000. Hedge funds and other institutional investors own 35.83% of the company’s stock.
Zosano Pharma Company Profile
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.
Recommended Story: Penny Stocks, Risk and Reward Factors
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.